Insider Transactions in Q4 2023 at Vyne Therapeutics Inc. (VYNE)
Insider Transaction List (Q4 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 13
2023
|
Iain Stuart CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
62,500
+46.62%
|
-
|
|
Dec 13
2023
|
Tyler Zeronda CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
62,500
+47.37%
|
-
|
|
Dec 13
2023
|
David Domzalski PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
225,000
+45.35%
|
-
|
|
Dec 13
2023
|
Mutya Harsch CHIEF LEGAL OFFICER AND GC |
BUY
Grant, award, or other acquisition
|
Direct |
62,500
+41.78%
|
-
|
|
Nov 30
2023
|
David Domzalski PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
2,284
+4.71%
|
$4,568
$2.81 P/Share
|
|
Nov 15
2023
|
Patrick G Lepore |
BUY
Open market or private purchase
|
Direct |
13,000
+26.28%
|
$39,000
$3.91 P/Share
|
|
Oct 02
2023
|
Tyler Zeronda CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,087
-13.56%
|
$3,261
$3.83 P/Share
|
|
Oct 02
2023
|
David Domzalski PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,549
-16.3%
|
$25,647
$3.83 P/Share
|
|
Oct 02
2023
|
Mutya Harsch CHIEF LEGAL OFFICER AND GC |
SELL
Payment of exercise price or tax liability
|
Direct |
1,154
-4.48%
|
$3,462
$3.83 P/Share
|
|
Oct 02
2023
|
Iain Stuart CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,184
-11.56%
|
$3,552
$3.83 P/Share
|